Automated and rapid chemiluminescence immunoassay for cardiac troponin I based on digital microfluidics

Rapid diagnosis of acute myocardial infarction (AMI) is critical in the clinical setting. An automated and rapid chemiluminescence immunoassay system based on digital microfluidics (DMF) is suggested for cardiac troponin I (cTnI). This method involves a double antibody sandwich structure. The cTnI antigen in the sample to be analyzed was captured by magnetic beads encapsulated with the cTnI antibody, which was subsequently recognized by the biotin-labeled secondary antibody. Horseradish peroxidase (HRP)-labeled streptavidin may be conjugated to biotin and used to mark the cTnI antigen because of the unique way that biotin binds to avidin. The simultaneous recognition of the cTnI antigen by primary and secondary antibodies in sandwich form, as well as the high specificity of the reaction between streptavidin and biotin, considerably improves the sensitivity and specificity of this technique for cTnI detection. This approach has decent stability. For cTnI samples, the full process took 40 min, with a limit of detection (LOD) of 0.34 ng mL(-1). Additionally, there was a significant correlation range from 0.39 to 25 ng mL(-1), with a correlation value of 0.994. The CV (Coefficient of variation) value was 2.26%. This system is anticipated to be used for the clinical measurement of cTnI in human serum.